Brewer E J, Giannini E H, Barkley E
Arthritis Rheum. 1980 Apr;23(4):404-11. doi: 10.1002/art.1780230403.
Gold therapy for 6 months was shown to be efficacious in reducing the severity of articular manifestations in 32 (63%) of 51 juvenile rheumatoid arthritis patients reviewed retrospectively. Similarly, reductions in the total number of involved joints were seen in 25 (49%) patients. Patients in whom a favorable response to therapy was noted had more severe joint involvement at the start of therapy than did nonresponders. In general, patients who responded experienced considerable improvement. Duration of disease prior to gold therapy initiation and disease onset type were not related to the probability of favorable response. Incidence of adverse side effects was low. Gold has recently been approved by the Food and Drug Administration for use in children.
回顾性分析51例青少年类风湿性关节炎患者，结果显示，接受6个月的金制剂治疗后，32例（63%）患者关节症状的严重程度有所减轻。同样，25例（49%）患者受累关节总数减少。与无反应者相比，对治疗有良好反应的患者在治疗开始时关节受累情况更严重。总体而言，有反应的患者病情有显著改善。开始金制剂治疗前的病程和发病类型与良好反应的可能性无关。不良反应发生率较低。金制剂最近已获美国食品药品监督管理局批准用于儿童。
